Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Nov 15

PMID 34778047

Citations 12

Authors

Jigang Chen

Mingyang Han

Aihua Liu

Bo Shi

Affiliations

Soon will be listed here.

Abstract

Background: The effectiveness of Sacituzumab Govitecan (SG) for metastatic triple-negative breast cancer (mTNBC) has been demonstrated. We aimed to evaluate its cost-effectiveness on mTNBC from the Chinese and United States (US) perspective.

Methods: A partitioned survival model was developed to compare the cost and effectiveness of SG single-agent chemotherapy based on clinical data from the ASCENT phase 3 randomized trial. Cost and utility data were obtained from the literature. The incremental cost-effectiveness ratio (ICER) was measured, and one-way and probabilistic sensitivity analyses (PSA) were performed to observe model stability. A Markov model was constructed to validate the results.

Results: In China, SG yielded an additional 0.35 quality-adjusted life-year (QALY) at an additional cost of Chinese Renminbi ¥2257842. The ICER was ¥6375856 ($924037)/QALY. In the US, SG yielded the same additional QALY at an extra cost of $175393 and the ICER was $494479/QALY. Similar results were obtained from the Markov model. One-way sensitivity analyses showed that SG price had the greatest impact on the ICER. PSA showed the probability of SG to be cost-effective when compared with chemotherapy was zero at the current willing-to-pay threshold of ¥217341/QALY and $150000/QALY in China and the US, respectively. The probability of cost-effectiveness of SG would approximate 50% if its price was reduced to ¥10.44/mg in China and $3.65/mg in the US.

Conclusion: SG is unlikely to be a cost-effective treatment of mTNBC at the current price both in China and the US.

Citing Articles

First-line chemotherapy with tislelizumab for patients with extensive-stage small cell lung cancer: a cost-effectiveness analysis.

Long R, Chen F Sci Rep. 2024; 14(1):31958.

PMID: 39738721 PMC: 11685972. DOI: 10.1038/s41598-024-83509-x.

Revolutionizing triple-negative metastatic breast cancer treatment: sacituzumab Govitecan's role in advancing chemotherapy.

Qureshi Z, Jamil A, Altaf F, Siddique R, Fatima E, Dost S Ann Med Surg (Lond). 2024; 86(9):5314-5319.

PMID: 39238964 PMC: 11374285. DOI: 10.1097/MS9.0000000000002347.

Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for metastatic triple-negative breast cancer: a trial-based analysis.

Wu Y, Hu S, Liu X, Chen Y, Luan J, Wang S Cost Eff Resour Alloc. 2024; 22(1):32.

PMID: 38659013 PMC: 11044338. DOI: 10.1186/s12962-024-00539-y.

Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany.

Wickmann A, Kurte M, Jeck J, Camacho L, Klinkhammer D, Kron F Cost Eff Resour Alloc. 2024; 22(1):21.

PMID: 38459569 PMC: 10924420. DOI: 10.1186/s12962-024-00528-1.

Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer.

Liang Y, Zhang P, Li F, Lai H, Qi T, Wang Y Front Pharmacol. 2024; 14:1332539.

PMID: 38352694 PMC: 10862125. DOI: 10.3389/fphar.2023.1332539.

References

Neumann P, Cohen J, Weinstein M . Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014; 371(9):796-7. DOI: 10.1056/NEJMp1405158. View

Huang X, Weng X, Lin S, Liu Y, Luo S, Wang H . Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis. BMJ Open. 2020; 10(8):e036107. PMC: 7462248. DOI: 10.1136/bmjopen-2019-036107. View

Starodub A, Ocean A, Shah M, Guarino M, Picozzi Jr V, Vahdat L . First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors. Clin Cancer Res. 2015; 21(17):3870-8. PMC: 4558321. DOI: 10.1158/1078-0432.CCR-14-3321. View

Wu B, Ma F . Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer. Ther Adv Med Oncol. 2020; 12:1758835920916000. PMC: 7222249. DOI: 10.1177/1758835920916000. View

Dranitsaris G, Yu B, King J, Kaura S, Zhang A . Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective. Clinicoecon Outcomes Res. 2015; 7:249-56. PMC: 4435086. DOI: 10.2147/CEOR.S82194. View

Rui M, Wang Y, Fei Z, Zhang X, Shang Y, Li H . Will the Markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments. Expert Rev Pharmacoecon Outcomes Res. 2021; 21(3):373-380. DOI: 10.1080/14737167.2021.1893167. View

Rui M, Shi F, Shang Y, Meng R, Li H . Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model. Adv Ther. 2020; 37(9):3761-3774. DOI: 10.1007/s12325-020-01418-7. View

Kruse G, Amonkar M, Smith G, Skonieczny D, Stavrakas S . Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population. J Manag Care Pharm. 2008; 14(9):844-57. PMC: 10438104. DOI: 10.18553/jmcp.2008.14.9.844. View

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D . Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Eur J Health Econ. 2013; 14(3):367-72. DOI: 10.1007/s10198-013-0471-6. View

10.

Bednova O, Leyton J . Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?. Int J Mol Sci. 2020; 21(19). PMC: 7582582. DOI: 10.3390/ijms21197268. View

11.

Petitjean A, Smith-Palmer J, Valentine W, Tehard B, Roze S . Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France. BMC Cancer. 2019; 19(1):140. PMC: 6371553. DOI: 10.1186/s12885-019-5335-8. View

12.

Glasziou P, Simes R, Gelber R . Quality adjusted survival analysis. Stat Med. 1990; 9(11):1259-76. DOI: 10.1002/sim.4780091106. View

13.

Sorensen S, Wern Goh J, Pan F, Chen C, Yardley D, Martin M . Incidence-based cost-of-illness model for metastatic breast cancer in the United States. Int J Technol Assess Health Care. 2012; 28(1):12-21. DOI: 10.1017/S026646231100064X. View

14.

Zhang Y, Zeng X, Deng H, Ma F, Peng Y, Yi L . Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR/HER2 Metastatic Breast Cancer From the US and Chinese Perspectives. Clin Ther. 2019; 41(6):1175-1185. DOI: 10.1016/j.clinthera.2019.04.033. View

15.

Garrido-Castro A, Lin N, Polyak K . Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019; 9(2):176-198. PMC: 6387871. DOI: 10.1158/2159-8290.CD-18-1177. View

16.

Khosravi-Shahi P, Cabezon-Gutierrez L, Custodio-Cabello S . Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies. Asia Pac J Clin Oncol. 2017; 14(1):32-39. DOI: 10.1111/ajco.12748. View

17.

Weng X, Huang X, Li H, Lin S, Rao X, Guo X . First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis. Am J Clin Oncol. 2020; 43(5):340-348. DOI: 10.1097/COC.0000000000000671. View

18.

Mistry R, May J, Suri G, Young K, Brixner D, Oderda G . Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective. J Manag Care Spec Pharm. 2018; 24(6):514-523. PMC: 10398120. DOI: 10.18553/jmcp.2018.24.6.514. View

19.

Rashid N, Koh H, Baca H, Lin K, Malecha S, Masaquel A . Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system. Breast Cancer (Dove Med Press). 2016; 8:173-181. PMC: 5063632. DOI: 10.2147/BCTT.S105618. View

20.

Guyot P, Ades A, Ouwens M, Welton N . Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012; 12:9. PMC: 3313891. DOI: 10.1186/1471-2288-12-9. View